Proof-of-concept study shows precision medicines could aid more people via RNA-targeting… When women or men receive the worrisome diagnosis of breast cancer, that news comes with an important piece of information, namely, whether their cancer is HER2-positive or HER2-negative. It can be especially difficult to hear that one’s cancer is HER2-negative, because it means an effective group of targeted anti-cancer drugs isn’t available. A new study from the lab of Scripps Research chemist Matthew D.